11.04.2013 - Fuelled by €1.1m of EU money, six European partners from industry and academia plan to find kinase-targeting drugs in a venture called TAKTIC.
A focussed group of three SMEs and three academic partners form the Translational Kinase Tumour Inhibitor Discovery Consortium (TAKTIC). Members announced on 10 April the creation of the consortium which is financed to the tune of €1.1m by the EU’s 7th Framework Programme “Research for the Benefit of SMEs”. The industry partners comprise SARomics Biostructures from Lund (Sweden), Prestwick Chemical from Illkirch (France) and ProQinase GmbH from Freiburg (Germany). The collaborating academic scientists work at the University of Turin (Italy) the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science and the TechMedIll platform of the University of Strasbourg (France).
Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium offers its members extensive expertise in medicinal chemistry, kinase biochemistry as well as state-of-the-art high-throughput platforms for protein expression and crystallisation. The merging of the highly complementary capabilities of the six partners within TAKTIC enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases, the partners said in a joint press release.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.
06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.